Which asthma inhaler works better? study pits advair against symbicort
NCT ID NCT01117116
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study compares two widely used asthma inhalers—Advair and Symbicort—to see if they have different effects on airway constriction. Researchers use a methacholine challenge test to measure how sensitive the airways are after four weeks of treatment. The study includes 20 adults with asthma who are already using a short-acting inhaler. Results may help guide which medication works best for individual patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fluticasone propionate and salmeterol (Advair) vs budesonide and formoterol (Symbicort)
- What this could lead to
- If one drug proves more effective at preventing airway constriction, it could help doctors choose the better treatment for asthma control.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply to everyone with asthma. Individual responses vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Start date
-
Mar 2010
- Finished
-
Sep 2013
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 20 subjects males or females 18-65 years of age with physician diagnosed asthma Diagnosis of asthma \> 12 months Currently on 2 puffs SABA bid. Baseline percent FEV1 of greater than 60% and less than or equal to 100% 12% reversibility in the previous 12 months 12% reversibility at Screening Visit Positive MTC (≤ 8mg/ml) at the end of 2 week Run-In Currently symptomatic with ACT score less than 19 at the end of run in on ICS ≥ 200 and ≤ 400 ug/day Non-smoker or ex-smoker with \< 10 pk year who stopped \> 1 year ago Exclusion Criteria: * Asthma exacerbation, significant airflow obstruction, or respiratory infection between Visits 0 and 2. Patients who fail screening because of one of these events may be re-screened once (at least 4 weeks after recovery from the event). Pre-existing lung disease other than asthma, including active infections Clinically significant medical disease that is uncontrolled despite treatment or is likely in the opinion of the investigator to require a change in therapy during the study Noncompliance or inability to participate in all assessments. Current smoker or former smoker with a lifetime smoking history of ≥ 10 pack-years. A current smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or a pipe or cigar) for \>/= 30 days within the 24 months prior to Visit 1. Any individual who smokes (cigarettes, marijuana, pipe, or cigar) occasionally, even if for \< 30 days in the 24 months Prior to Visit 1, must agree to abstain from all smoking from the time of consent through completion. History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator. Participation in another interventional clinical trial (including a trial of an approved drug or an interventional study that does not include medication) within 30 days or 5 half-lives of the investigational agent, whichever is longer. Women with a positive urine pregnancy test.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Jewish Health
Denver, Colorado, 80206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single triple inhaler tame asthma in the real world?
- Can a Three-Drug inhaler outperform the standard Two-Drug treatment for asthma?
- Can a new inhaler match Symbicort's performance?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- Can a hormone supplement tame asthma?
- A wearable stethoscope may let kids with asthma monitor their lungs at home